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Abstract: 
Background: 
ELBW preterm infants are at extremely high risk for adverse neurodevelopmental 
(ND) outcome. Systemic hypotension is an important peri-natal risk factor in 
neurodevelopmental outcome. Numerous other risk factors exist for adverse 
neurodevelopmental outcome. 
Aim: 
To assess whether early mean systemic blood pressure and other risk factors 
contribute to poor ND outcome in ELBW preterm infants managed at Panorama 
Medi-Clinic. 
Methods: 
A retrospective, analytical study using data obtained from 2003 to 2008.  Data 
from the Vermont Oxford Network database of which Panorama Medi-Clinic is a 
member was used to select a cohort of inborn, surviving infants weighing ≤ 1000g 
or ≤ 30 weeks gestational age. Early mean systemic BP records were obtained 
from nursing records. ND data was obtained from the neurodevelopmental clinic or 
routine follow up clinics notes. Infants with major defects at birth were excluded. 
The cohort was classified according to their general developmental quotient and 
whether or not they had signs of cerebral palsy into a normal or abnormal 
neurodevelopmental group.  All patients remained completely anonymous and 
ethical clearance was obtained from the ethics committee at Panorama Medi-
Clinic.   
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Results: 
 82 infants were eligible. 78 were entered the study. 4 were lost to follow up. 
Average birth weight was 782.1g ± 148.23. Average gestational age was 27.06w ± 
1.32.  Normal neurodevelopmental outcome was found in 64(82%). An abnormal 
neurodevelopmental outcome was found in 14(18%).  
No statistically significant difference was found by logistical regression when mean 
systemic blood was compared between normal and abnormal neurodevelopmental 
groups. 
If a cut off BP of <30 mm Hg, or inotropic agents were administered, no statistical 
difference was found between the normal and abnormal groups. 
Severe grades of IVH, ROP, post-natal steroids, and chronic lung disease, and 
gastro-intestinal perforation, were identified as risk factor of adverse outcome.  
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Conclusion: 
Early mean systemic blood pressure could not be identified as a risk factor in 
neurodevelopmental outcome, nor could we show that a cut off in mean systemic 
blood pressure < 30 mmHg (our definition of systemic hypotension) is associated 
with adverse neurodevelopmental outcome.  
Inotropic usage to improve early mean systolic blood pressure is not associated 
with adverse neurodevelopmental outcome.  
We confirmed that, severe grades of IVH and ROP, postnatal steroids, chronic 
lung disease, and gastrointestinal perforation are important risk factors for adverse 
neurodevelopmental outcome.  
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Abbreviations Key: 
NICU= Neonatal intensive care unit 
VON= Vermont Oxford Network  
ELBW= Extremely Low Birth weight  
CLD= Chronic Lung Disease 
CP= Cerebral palsy 
MDI= Mean developmental Index 
PDA= Patent ductus arteriosus 
NEC= Necrotizing enterocolitis 
IVH= Intraventricular Haemorrhage 
ROP= Retinopathy of Prematurity 
PVL=Periventricular leucomalacia 
 
 
 
 
 
 
P a g e  | X 
 
 
List of Tables: 
Table 1:  Cohort Demographics 
Table 2:  Cohort Demographic and Risk Factor data pertaining to  
                 selected cohort 
Table 3: Analysis of Various Risk factors for Normal and Abnormal            
                 Neurodevelopmental Outcome and Statistical Significance 
Table 4: Normal versus Abnormal Neurodevelopment Where No Cut     
                 Off in Mean Systemic Blood Pressure Used 
Table 5: Statistical Comparison of Normal versus Abnormal     
                 Neurodevelopment where Cut Off Applied of Mean Systemic BP below   
                 30 mmHg 
Table 6: Statistical Comparison of Normal and Abnormal Neurodevelopmental   
                Outcomes where Inotropic Support were used within first 24 Hours life 
 
 
 
 
 
P a g e  | XI 
 
 
List of Figures: 
Figure 1: Microglia as a convergence point for upstream and 
                  downstream mechanisms in pathogenesis
P a g e  | 1 
 
 
1. Introduction: 
Over the last two decades the survival of extremely low birth weight infants has 
been steadily increasing due to improved neonatal intensive care1,2. However, 
morbidity free survival, has not kept pace with the improved survival of the 
ELBW preterm infant.  Morbidity in these ELBW premature infants often 
involves neurodevelopmental disabilities which may be present despite normal 
brain ultrasounds3. The classical lesions seen in the very premature infant occur 
in the white matter at vascular border zones where the poorly developed 
ventriculo-pedal and ventriculo-fugal arteries feed deep white matter. Other 
more subtle damage, as well as damage to the deep grey matter particularly the 
thalami, is now being described due to modern MRI imaging and PET scanning 
techniques as well as neuropathological studies4,5,6. Hypotension is present in 
up to 45% of ELBW infants and its incidence is inversely proportional to the 
gestational age of the infant7. Poor cerebral perfusion due to hypotension 
aggravated by an inability to auto-regulate and maintain adequate cerebral 
perfusion, as well as inflammation of the white matter due to chorioamnionitis, 
ultimately results in damage of the white and grey matter4,8,9.  
Khwaja and Volpe eloquently explain how hypoxia and ischaemia together with 
inflammation result in microglial cell activation and ultimately oligodendrocyte 
death due to cytokine, oxidative free radical (ROS), free nitrogen species (RNS) 
and glutamate release10. See Fig. 1 below 
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Figure 1. Pathogenesis of cerebral white matter injury of prematurity 
(Khwaja O, Volpe JJ: Pathogenesis of Cerebral White matter Injury of 
Prematurity. Arch Dis Child Fetal Neonatal Ed. 2008 Mar;93(2):F153-61 
Review, Figure 3, page F155,  Microglia as a convergence point for 
upstream and downstream mechanisms in pathogensis)10 
 
 The perfusion of the very immature infant`s brain, particularly the watershed 
areas described above, has been thought to be pressure dependent and 
therefore dependent on systemic blood pressure for adequate perfusion of the 
deep white and grey matter. Unfortunately, scientifically proven normal values 
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for early systemic mean blood pressures do not exist for this group of preterm 
infants as most of these infants are not born healthy and most require 
ventilatory and other intensive care support in order for them to survive. 
Clinicians therefore have to rely on unsubstantiated normal values such as a 
mean systemic blood pressure equivalent to the gestational age of the infant 
and other assumed values to evaluate normal systemic blood pressure. Values 
derived using the gestational age and mean blood pressure are the most 
commonly cited in various articles and have no research proven validity. They 
also do not take into account whether other vital organs are being adequately 
perfused or not, and are at best simplistic. It is up to the clinician to make 
correct judgments regarding the latter and to assess other parameters of the 
infant’s wellbeing which might maintain or improve cerebral blood flow and 
therefore limit prolonged hypoperfusion and prevent white matter ischaemia and 
damage. 
Systemic mean blood pressure, or hypotension, might therefore be an important 
risk factor (by no means the only one) in the neurodevelopmental outcome of 
extremely low birth weight infants. 
This study investigates the early mean blood pressure of a group of ELBW 
preterm infants as a possible risk factor in early neurodevelopmental outcome. 
In our NICU we aim at maintaining the early mean systemic blood pressure 
above 30mmHg and do not accept the definition of hypotension as being a 
mean BP below the gestational age of the infant. Hence we define hypotension 
as a mean systemic arterial blood pressure less than 30mmHg. 
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2. Literature Review:  
Improved neonatal care of extremely low birth weight (ELBW) preterm infants 
over the last two decades has resulted in vastly improved survival of ELBW 
infants.  Despite improved survival, numerous studies have shown that many of 
these survivors are left with major long term developmental deficits1,2.  
Poor neurodevelopmental outcome has been proven to be associated with a 
number of peri- and post-natal risk factors11.  Laptook A.R. et al showed that 
nearly 30% of ELBW infants with a normal head ultrasound (HUS) either had 
CP or a low MDI3. 
 It was suggested that risk factors associated with this high rate of adverse 
outcomes include pneumothorax, prolonged exposure to mechanical ventilation, 
and educational and economic disadvantage. Many questions remain with 
regards to other risk factors that possibly underlie abnormal 
neurodevelopmental outcome in ELBW preterm infants. Systemic hypotension 
has been shown to be associated with poor neurodevelopmental outcome in 
ELBW preterm infants12.  
The cerebral perfusion of the ELBW infant is extremely vulnerable to even 
minor systemic blood pressure changes because of immature auto-
regulation10,12. ELBW preterm infants rely on perfusion pressure for cerebral 
perfusion as normal auto-regulation mechanisms for the maintenance of 
adequate cerebral perfusion, particularly watershed areas, has been shown to 
be inadequate when there is associated systemic hypotension13,14. Systemic 
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hypotension and subsequent ischaemia of deep white matter, along with 
inflammation, has been shown to be one of the most important causes of white 
matter injury in ELBW infants10,15. Hence, the effect of systemic blood pressure 
levels / changes during the first 12 hours of life might be an important risk factor 
for the development of periventricular leucomalacia (PVL) as well as 
intraventricular haemorrhages as well as more subtle damage to the immature 
brain, ultimately leading to adverse neurodevelopmental outcome.   
Another dilemma is the lack of normal systemic blood pressures values for 
ELBW preterm infants in the first hours to days of life and hence there is no 
clear definition of hypotension in the extremely low birth weight preterm infant16. 
Normal and more importantly adequate mean systemic blood pressure values 
have thus far not been firmly established in the scientific literature for these 
infants and still remains controversial. A common but unproven definition (rule 
of thumb) of normal blood pressure, assumed in many studies, is that the mean 
systemic blood pressure should not fall below the gestational age of the infant. 
Unfortunately, because there are no seminal scientific studies which define 
normal blood pressure in ELBW infants, we have to rely on extrapolations from 
studies done in more mature infants, which might be inappropriate in the setting 
of ELBW infants17,18. Our definition of hypotension is a mean systemic BP < 
30mmHg and is independent of the gestational age of the infant. 
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3.Null Hypothesis 
    3.1 Primary Hypothesis 
           Early Mean Systemic Arterial Blood pressure is not associated with poor    
           Neurodevelopmental Outcome in Extremely Low Birth Weight Preterm   
           Infants 
  3.2 Alternative Hypothesis 
          Early mean systemic arterial blood pressure is associated with poor   
          Neurodevelopmental Outcome in Extremely Low Birth weight Preterm  
          Infants 
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4.Objectives: 
4.1 Primary Objectives:  
           To determine the effect of mean systemic blood pressure during the first  
           12 hours of life birth on neurodevelopmental outcome of a cohort of  
            ELBW preterm infants. 
     4.2 Secondary Objectives: 
1. To report on the effect of early inotropic administration to support  
systemic blood pressure on the neurodevelopmental outcomes of 
ELBW preterm infants. 
2. To report on the incidence and assess the statistical significance of 
the following risk factors in neurodevelopmental outcomes in ELBW 
preterm infants 
2.1  Severe IVH (grades 3 and 4) 
     2.2  Periventricular Leucomalacia 
     2.3  Severe ROP (Grades 3 and 4) 
     2.4 CLD (Oxygen dependency at 36 weeks post conceptual age) 
     2.5 NEC 
     2.6 NEC requiring surgery 
     2.7 Patent ductus arteriosus 
                2.8 Pneumothorax 
                2.9 Late onset sepsis 
                2.10 Duration of oxygen dependency 
                2.11 Length of Hospitalization 
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5. Methods:  
A cohort of extremely low birth weight and gestational age preterm infants 
treated at the Panorama Medi-Clinic Neonatal Intensive Care Unit were 
selected using the Vermont Oxford database. The NICU at Panorama Medi-
Clinic is a member of the Vermont Oxford Network Database (VON).  The 
VON is a non-profit collaborative of health care professionals interested in 
promoting and improving the quality and safety of medical care of newborn 
infants and their families19. The Panorama Medi-Clinic submits all of its data into 
the VON database. The cohort used in this research report was selected from 
the VON Database. 
 
6. Inclusion Criteria:  
All infants’ ≤1000g and ≤ 30 weeks gestation consecutively inborn at Panorama 
Medi-Clinic and admitted to the Panorama Medi-Clinic NICU were selected from 
the VON database from 2003 till 2008.  
A cohort of 78 infants was studied. 
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7. Exclusion Criteria:  
The following patients were excluded: 
1. Outborn infants- infants born at other hospitals and transferred to Panorama 
Medi-Clinic for further management. 
2. Infants ≤1000g but > 30 weeks gestational age at delivery. 
3. Patients with severe or fatal congenital abnormalities.  
4. Patients who were completely lost to follow up. 
5. Infants who died before discharge. 
6. Patients in whom no clinical notes were available. 
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8. Data Collection: 
Information was retrieved retrospectively from neonatal charts, nursing records 
and the electronically compiled Vermont Oxford Network database. 
Apart from the relevant demographic data for each of the cohort the following 
additional information was collected for each of the cohort:  
1. Mean systemic blood pressure was obtained from nursing observation 
charts. All these readings were obtained from indwelling peripheral arterial 
cannulae or central umbilical arterial lines. The first recordings were noted 
once the infant`s line had been inserted in the NICU. The next recordings 
were made at 6 and 12 hours of age.  
2. Inotropic use during the first 24 hours was obtained from Nursing records or 
clinical notes and included the use of Dopamine (Intropin®), Dobutamine 
(Dobutrex®) and adrenalin / epinephrine.  
3. Neurodevelopmental data was obtained in the following manner:  
      From the Neurodevelopmental Follow up clinic: 
           An established high risk neurodevelopmental clinic exists at Panorama  
           Medi-Clinic. High risk preterm infants are followed up a 4½ months, 8  
           months and 12 months, 18 months and 2 yrs corrected age. The follow  
           up team consists of an experienced neurodevelopmental paediatrician,  
           as well as an experienced neurodevelopmentally trained (NDT)  
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         Physiotherapist. The same paediatrician and physiotherapist were  
         used in all the follow up visits at this clinic. During each follow up  
         session a complete neurological examination was performed looking  
         specifically for signs of cerebral palsy. 
         An Infant Neuromotor Assessment (INA) (up to 12months)   
         was carried out on each patient under 1 year of age and any deviations  
         from the norm noted20. 
         A Molteno Adapted Scale assessment was performed at each  
         visit up  to 2 years of age. The Molteno Adapted Scale allows for a   
         developmental quotient to be obtained for gross motor, fine motor,  
         communication and personal-social categories. A general  
         developmental quotient can then be derived for the specific patient   
         by deriving the average of the 4 developmental quotients from the   
         above 4 developmental domains assessed. This developmental    
         screening tool has been shown in an MSc thesis submitted to the   
         University of  Witwatersrand by Dr. B. Laughton to have a close  
         correlation with the Griffiths Mental Developmental Scales performed at  
         2 yrs of age21.  
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         A Griffiths Mental Development Scales assessment was performed    
        at approximately 24months corrected age by the same  
        Neurodevelopmental Paediatrician. This is a formal standardized  
        developmental screening tool and a developmental quotient is obtained  
        for Gross motor, Fine Motor, Speech and Language, Personal-Social  
        and Performance scales. A general developmental quotient is then  
        derived for each patient as an average of the 5 developmental  
        quotients in the 5 domains examined in the Griffiths Mental  
        Developmental Scale. 
        Follow up Visits to Paediatrician – Developmental information was also  
        reviewed in clinical records of patients who had not had any or only  
        incomplete formal assessments, or where no formal assessments were  
        performed. 
The survivors’ Neurodevelopmental Outcome was then classified into the    
 following categories: 
Normal- If the patient has no clinical signs of cerebral palsy and general     
              developmental quotient was ≥ 90. 
Abnormal – If the patient had either a clinical diagnosis of cerebral palsy and/or  
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                     general developmental quotient of <90 
 
9. Time Frame:  
      Inborn infants weighing ≤1000g and ≤30 weeks gestational age born from  
1 January 2003 till 31 December 2008 were included in the study cohort. 
 
10. Study Limitations:  
     This study has the following limitations: 
     Retrospective data and analysis has been used in this study 
     A relatively small sample size of infants has been used. 
     Blood pressure readings were only taken at 3 specific times after birth and 
not    
     continuously, as this was not possible given the retrospective nature of the   
     study   
     The study uses information over a relatively long period, namely 5 years, 
during      
     which there might have been policy changes in the management of the 
cohort     
     defined above. For example the delivery room resuscitation and early   
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     management of these infants with in/out surfactant and Nasal CPAP.   
     The neurodevelopmental follow up of these infants was assessed up until    
     approximately two years of age. Many studies by a number of authors have  
     cast doubt on the accuracy of follow up only until this age as more subtle    
     deficits might become manifest only later in these survivors life22.   
     Infants who died before discharge were excluded from the study cohort and    
     might have had complications due to hypotension early in life. 
 
 
11. Statistical Analysis:  
Characteristics, treatments and outcomes were compared between survivors 
with abnormal and/or suspected abnormal neurodevelopmental outcome and 
those surviving without any handicap by using univariate analysis. Continuous 
variables were compared with Student’s t test, whereas dichotomous variables 
were assessed with the chi-square statistic with correction for multiple 
comparisons. Logistic regression adjusted for birth weight, gestational age, 
gender, antenatal steroid treatment, small for gestational age and severe IVH 
were used to test the relationship between neurodevelopmental outcome and 
hypotension and a separate logistic regression was used to test the effect 
modification by hypotension.  
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12. Human Subject Protection: 
This Study uses retrospective data that has already been captured and no 
patient names and other identifying information will be published. 
 
13. Funding: 
This study was privately funded, including the statistical analysis. 
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14. Results: 
      Demographic: 
      82 ELBW infants were found to be eligible for the study between  
      1 January 2003 and 31 December 2008. 
       Of these infants 4 infants were excluded because of insufficient data or loss        
       to   follow up.  Data pertaining to the remaining 78(95.1%) infants was used   
       for the study. See table 1 below. 
                               Table 1: Cohort Demographics:  
Infants Numbers(%) 
Study Cohort 82(100) 
Year 2003-2008 
Lost to Follow Up 4(4.9) 
Follow up N(%) 78(95.1) 
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      Table 2: Cohort Demographic and Risk Factor data pertaining to  
                     selected cohort: 
DEMOGRAPHIC/ 
RISK FACTOR 
Overall 
Value 
N(%) 
Normal 
Neurodevelopmental 
Outcome 
N(%) 
Abnormal 
Neurodevelopmental 
Outcome 
N(%) 
Inborn 78(100) 64(82) 14(18) 
Birth weight (g)± SD 782.1 ± 
148.23 
787.42 ± 142.39 757.86 ± 176.38 
Gestational Age(w)± SD 27.06 ± 1.32 27.09 ± 1.28 26.92 ± 1.54 
Sex (M:F)(M%) 31:47(40) 23:41(36) 8:6(57) 
1’ Apgar Score ± SD 5.94 ± 2.17 5.97 ± 2.16 5.79 ± 2.29 
5’ Apgar Score ± SD 8.03 ± 1.26 7.98 ± 1.33 8.21 ± 0.89 
Antenatal Steroid 72(92.3) 60(93.8) 12(85.7) 
Mode Delivery C/S 73(93.6) 61(95.3) 12(85.7) 
Multiples 27(34.6) 23(35.9) 4(28.6) 
Respiratory Distress 
Syndrome 
78(100) 64(100) 14(100) 
 
Of the eligible 78 infants 64(82%) were found to have a normal 
neurodevelopmental outcome according to our definition, i.e., a General 
Quotient of ≥90 and no signs of any cerebral palsy. 14(18%) infants had 
abnormal developmental outcomes defined as either a General Developmental 
Quotient <90 and / or signs of cerebral palsy.  
The mean gestational age was 27.06 weeks and there was no statistical 
significant difference between those with normal or abnormal 
neurodevelopment. 
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No statistically significant difference could be found between the sex 
distribution, Apgar scores at 1` or 5`, antenatal steroid usage, mode of delivery, 
or multiple pregnancy. 
100% of the cohort in both normal and abnormal neurodevelopmental outcome 
groups developed respiratory distress, however not all required intubation and 
active ventilation.   
In Table 3 below, 18 different risk factors which were included as part of the 
secondary objectives were statistically analysed between the normal and 
abnormal neurodevelopmental outcome groups. No statistical significant 
difference was noted between the two groups for the following: 
1. Pneumothorax, 
2.  Exogenous surfactant, 
3.  Patent ductus arteriosus (confirmed by echocardiography), 
4.  Indomethacin usage for PDA, 
5.  Surgical ligation of PDA,  
6. Necrotizing enterocolitis, 
7. Late onset sepsis, 
8. Retinopathy of Prematurity, ROP (grade 1&2), 
9. Intraventricular Haemorrhage, IVH(grade 1&2), 
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10. Discharge weight, 
11. Oxygen dependency on discharge and, 
12. Length of stay in hospital. 
 
 Statistical significant differences (p<0.05) were found for the following: 
1. Severe grades of Intraventricular Haemorrhage IVH(grade3&4), 
2. Retinopathy of Prematurity, ROP(grade 3&4), 
3. Postnatal steroid usage, 
4. Chronic lung disease defined as oxygen dependency at 36 weeks post- 
    conceptual age, as well as for, 
5. Gastrointestinal perforation 
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       Table 3: Analysis of Various Risk factors for Normal and Abnormal     
                      Neurodevelopmental Outcome and Statistical Significance:  
RISK FACTORS Overall Value Normal 
Neurodevelopmental 
outcome 
N(%) 
Abnormal 
Neurodevelopmental 
outcome 
N(%)    * p< 0.05 
Pneumothorax 1(1.3) 0(0) 1(7.1) 
Exogenous 
Surfactant 
71(91.0) 58(90.6) 13(92.9) 
PDA(Echo) 50(64.1) 39(60.9) 11(78.6) 
Indomethacin 44(56.4) 33(51.6) 11(78.6) 
PDA Ligation 3(3.8) 3(4.7) 0(0) 
G-I perforation 2(2.6) 0(0) 2(14.3)* 
NEC 3(3.8) 1(1.6) 2(14.3) 
Late Onset Sepsis 18(23.1) 13(20.3) 5(35.7) 
ROP(Grade1&2) 27(34.6) 21(32.8) 6(42.9) 
ROP(grade3&4) 2(2.6) 0(0) 2(14.3)* 
Post Natal Steroids 38(48.7) 27(42.2) 11(78.6)* 
Oxygen at 36 
weeks PCA 
27(34.6) 18(28.1) 9(64.3)* 
IVH(Grade 1&2) 10(12.8) 9(14.1) 1(7.1) 
IVH(Grade 3&4) 1(1.3) 0(0) 1(7.1)* 
PVL 2(2.6) 1(1.5) 1(7.1) 
Discharge 
Weight(grams) 
2266.85±551.14 2263.73±439.16 2281.07±929.68 
Oxygen at 
Discharge 
8(10.3) 6(9.4) 2(14.2) 
Length of Stay(d) 86.22±39.60 87.80±41.32 95.71±31.02 
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In Table 4 below, the mean systemic BP was compared in the normal and 
abnormal neurodevelopmental groups at three intervals beginning with the first 
recorded BP in the NICU and subsequently at 6 and 12 hours postnatal age 
with a generalised linear regression model. No statistical significant difference 
was found between the two groups. 
Table 4: Results of Normal versus Abnormal Neurodevelopment Where No      
              Cut Off in Mean Systemic Blood Pressure Used: 
Measurement 
No Cut Off 
Normal 
Neurodevelopment 
Abnormal 
Neurodevelopment 
p-value 
 Mean	  BP	  ±	  SD	  (mmHg) Mean	  BP	  ±	  SD	  (mmHg) Significance 
1St Mean BP 30.33 ± 6.23 29.93 ± 7.17 NS 
6 Hours 36.38 ± 6.33 37.50 ± 4.86 NS 
12 Hours 36.00 ± 4.99 36.57 ± 6.68 NS 
 
In table 5 below, a comparison was performed between the normal and 
abnormal neurodevelopmental groups where the mean systemic blood pressure 
was less than 30 mmHg at the three periods defined above. No statistical 
difference could be found using a linear regression model between those with 
normal or abnormal neurodevelopmental outcomes.  
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Table 5: Results of Statistical Comparison of Normal versus Abnormal   
              Neurodevelopment where Cut Off Applied of Mean Systemic BP  
              Below 30 mmHg:  
Measurement 
Cut Off 
<30 mmHg 
Normal 
Neurodevelopmental 
Outcome 
Abnormal 
Neurodevelopmental 
Outcome 
p-Value 
 N(%)  N(%)  Significance  
1St Mean BP 30(46.9)  7(50.0)  NS  
6 Hours 6(9.4)  1(7.1) NS  
12 Hours 4(6.3) 1(7.1) NS  
 
 
Table 6: Statistical Comparison of Normal and Abnormal         
               Neurodevelopmental Outcomes where Inotropic Support where  
              used Within first 24 Hours life:   
Risk Factor Normal 
Neurodevelopmental 
Outcome 
N=64 
Abnormal 
Neurodevelopmental 
Outcome 
N=14 
Pearsons 
Chi 2 
Test 
 N(%) N(%)  
Inotropes 
First 24 
Hours 
27(42.2) 5(35.7) NS 
 
 
 
In table 6 above the developmental outcomes of all the infants who were given 
inotropic support during the first 24 hours are compared statistically using the 
Pearson`s Chi2 test. No statistical difference was found between the normal and 
abnormal neurodevelopmental groups. 
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15. Discussion: 
The aim of this study was to assess if mean systemic blood pressure is a risk 
factor for poor neurodevelopmental outcome in a cohort of ELBW infants 
managed at Panorama Medi-Clinic. The secondary objectives were to identify 
whether inotropic usage, a marker of cardiovascular instability as well as other 
risk factors contributed to poor neurodevelopmental outcome in ELBW infants. 
ELBW premature infants are at a high risk for neurodevelopmental disabilities. 
The incidence of neurodevelopmental disability has not improved over the last 
two decades despite the great strides made with regards to improved survival. 
A variety of risk factors have been implicated in determining 
neurodevelopmental outcome in survivors.  
Cerebral hypoperfusion owing to systemic hypotension in ELBW infants has 
been cited as a risk factor that might be responsible for damage to both white 
and grey matter structure hence leading to neurodevelopmental disabilities in 
these immature infants9,10. It is assumed from a number of animal studies that 
the intrinsic vaso-regulatory mechanisms found in more mature infant humans 
are not functional in these very immature infants, particularly ill ELBW infants. 
These infants who might be hypotensive are therefore at risk of cerebral 
hypoperfusion as they are unable to maintained adequate cerebral perfusion 
particularly in vulnerable watershed zones owing to perfusion being a pressure 
passive phenomenon.  A recent article by Lightburn et al has shown that 
perhaps this is not the case and that perfusion as measured by cerebral blood 
flow velocities is maintained despite hypotension in these ELBW infants17. 
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Nevertheless, prolonged, severe episodes of hypotension in these infants might 
be the cause of later neurodevelopmental disabilities due to ischaemic damage 
to deep white and grey matter in the developing brains of ELBW infants5.  
 In our study cohort we were unable to demonstrate using a logistical regression 
analysis correcting for birth weight, gestational age, gender, antenatal steroid 
treatment, small for gestational age and severe IVH, a statistically significant 
effect of mean systemic blood pressure and adverse neurodevelopmental 
outcome.  
Normal values for systemic blood pressure according to the gestational age and 
chronological age of the ELBW infant is at present controversial and poorly 
defined in the literature. In most studies looking at systemic blood pressure in 
the ELBW infant, non-validated generalized values are used where hypotension 
is defined as a mean systemic blood pressure lower than a value equivalent to 
the gestational age of the infants, for example, in a 26 week gestational age 
infant, infant is hypotensive if its mean systemic blood pressure is below 26 mm 
Hg, etc23. However, other definitions such as < 10th percentile of gestational age 
and postnatal age according to published norms, and <30 mmHg can also be 
used and are perhaps more accurate17. 
In our NICU we aim at maintaining a mean systemic BP above 30 mmHg 
particularly when there is no spontaneous increase in mean systemic blood 
pressure over time. Our definition of systemic hypotension is therefore a mean 
systemic BP of <30mmHg. This is achieved by firstly giving fluid challenges in 
the form of stabilized human serum or normal saline and if there is a poor 
P a g e  | 25 
 
 
response then inotropic medication is commenced. It is also well described that 
infants who remain hypotensive for prolonged periods of time are at risk for 
developing intraventricular bleeds18,24,25. Unfortunately this study being a 
retrospective one assesses systemic blood pressure only at three specific post 
natal ages. It does not assess continuous blood pressure or more specifically 
cerebral perfusion.  
 We were unable to confirm the poorer neurodevelopmental outcome and an 
increase in sensorineural deafness in these infants if they were treated for 
hypotension as previously reported by Fanaroff and co-workers26.  
Management policies in our NICU have changed over the last couple of years 
and more of these ELBW infants are receiving in-out surfactant in the ICU and 
fewer infants are being actively intubated and ventilated in the delivery room. 
This may have had an impact on survival as well as stabilizing the infant from a 
hemodynamic point of view. Delayed cord clamping has also been shown to 
improve blood volume and this intervention has been introduced in the last 
approximately 2 years of this study period27. Both the above new interventions 
might have had an impact on systemic blood pressure in these ELBW infants 
and resulted in improved mean systemic blood pressure and therefore improved 
cerebral perfusion and neurodevelopmental outcome. 
A cut off value for mean systemic blood pressure of < 30 mmHg was used to 
assess if we could demonstrate a particular minimum threshold mean systemic 
blood pressure below which one could prove a statistical difference between the 
normal and abnormal neurodevelopmental outcome groups (see table 5 
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results). Again we were unable to find a statistically significant difference 
between the normal and abnormal outcome groups. This could be because the 
small number of infants who fell into this category or because of our policy of 
attempting to maintain a mean systolic pressure above 30mmHg and therefore 
although there might have been a brief period where the mean systemic blood 
pressure was recorded below 30 mm Hg this was never prolonged enough so 
as to have an adverse neurodevelopmental effect. 
Fanaroff et al in his study showed a poorer neurodevelopmental outcome in 
ELBW infants who were treated for hypotension with inotropic agents26.  In our 
study the normal and abnormal groups who received inotropic support in the 
first 24 hours were compared and again no statistical difference in 
neurodevelopmental outcome could be demonstrated (see table 6). 
Other risk factors (see table 3 and 4) for abnormal neurodevelopmental 
outcome identified as secondary variables to explain significant differences 
between the normal and abnormal neurodevelopmental outcome groups. Of 
these risk factors the following were found to have statistical significance:  
1. Severe grades of Intraventricular Haemorrhage IVH(grade3&4), 
2. Retinopathy of Prematurity, ROP(grade 3&4), 
3. Postnatal steroid usage, 
4. Chronic lung disease defined as oxygen dependency at 36 weeks post 
conceptual age, as well as for, 
5. Gastrointestinal perforation. 
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16. Conclusion: 
This study was unable to prove that early mean systemic blood pressure is a 
risk factor for poor neurodevelopmental outcome in extremely low birth 
weight infants even if a cut off level of <30 mm Hg is used to define 
hypotension. We were able to show that severe grades of intraventricular 
haemorrhage and retinopathy of prematurity, postnatal steroid usage, 
chronic lung disease and gastrointestinal perforation are associated with 
adverse neurodevelopmental outcome in extremely low birth weight infants 
treated at out institution.    
 
 
 
 
 
 
 
 
 
 
P a g e  | 28 
 
 
17. References: 
1. Fanaroff AA, Stoll BJ, Wright LL, et al:  Trends in Neonatal Morbidity 
and Mortality for Very Low Birthweight Infants. Am J Obstet Gynecol. 
2007 Feb;196(2):147.e1-8.  
2. Arpino C, Compagnone E, Montanaro ML, et al: Preterm Birth and 
Neurodevelopmental Outcome- Review. Childs Nerv Syst 2010; Mar 
27 (epub ahead of print) 
3. Laptook AR, O`Shea TM, Shankaran S, et al: Adverse 
Neurodevelopmental Outcomes Among Extremely Low Birth 
Weight Infants with a Normal Head Ultrasound: Prevalence and 
Antecedents. Pediatrics 2005;115:673-680 
4. Pierson CR, Folkerth RD, Billiards SS, et al: Grey Matter Injury 
Associated with Periventricular Leukomalacia in the Premature 
infant. 
     Acta Neuropathol 2007; 114:619–631 
5. Inder TE, Warfield SK, Wang H, et al: Abnormal Cerebral Structure in 
Present at Term in Premature Infants. Pediatrics 2005;115:286-94 
6. Srinivasan L, Dutta R, Counsell SJ,  et al: Quantification of Deep gray 
Matter in Preterm Infants at Term-Equivalent Age using Manual 
Volumetry of 3-Tesla Magnetic Resonance Imaging.  Pediatrics 
2007;119:759-65 
 
 
P a g e  | 29 
 
 
7. Efird MM, Heerens, AT, Gordon PV, et al:  A Randomized-Controlled 
Trial of Prophylactic Hydrocortisone Supplementation for the 
Prevention of Hypotension in Extremely Low Birth Weight Infants.  
J Perinatol 2005; 25:119-124 
8. Kaukola T, Herva RA, Perhomaa M, et al: Population Cohort 
Associating Chorioamnionitis, Cord Inflammatory Cytokines and 
Neurological Outcome in very Preterm, Extremely Low Birth Weight 
Infants. Pediatr Res 2006 Mar; 59(3):478-83 
9. Resch B, Vollaard E, Maurer U, et al: Risk factors and Determinants of 
Neurodevelopmental Outcome in Cystic Periventricular 
Leucomalacia. Euro J Pediatr 2000 Sep; 159(9):663-7 
10. Khwaja O, Volpe JJ: Pathogenesis of Cerebral White matter Injury of 
Prematurity. Arch Dis Child Fetal Neonatal Ed. 2008 Mar; 93(2):F153-
61 Review 
11. Cooke R : Perinatal and Postnatal Factors in Very Preterm Infants 
and subsequent Cognitive and Motor Abilities.  Arch Dis Child Fetal 
Ed 2005; 90: F60-3  
12. Fanaroff AA, Fanaroff J.M.:Short- and Long-Term Consequences of 
Hypotension in ELBW infants. Semin Perintol 2006; 30:151-155  
13. Young RS,  Hernandez MJ, Yagel SK: Selective Reduction of Blood 
Flow to White Matter during Hypotension in Newborn Dogs: A 
Possible Mechanism of Periventricular Leucomalacia. Ann Neurol  
Nov 1982; 12(5):445-448 
P a g e  | 30 
 
 
14.  Munro MJ, Walker AM, Barfield CP: Hypotensive Extremely Low 
Birth Weight Infants have Reduced Cerebral Blood Flow. Pediatrics 
Vol 114(6)Dec. 2004:1591-6 
15. Adams-Chapman I,  Stoll BJ: Neonatal Infection and Long-term 
Neurodevelopmental Outcome in the Preterm Infant. Curr Opin Infect 
Dis. 2006 Jun; 19(3):290-7  
16. Kuint J, Barak M, Morag I, et al: Early treated Hypotension and 
Outcome in Very Low Birth Weight Infants. Neonatology 2009; 
95(4):311-316 
17. Lightburn MH, Gauss CH, Williams DK,  et al: Cerebral Blood Flow 
Velocities in Extremely Low Birth Weight Infants with Hypotension 
and Infants with Normal Blood Pressure. 	  J Pediatr 2009;154:824-8  
18. Watkins AM, West CR, Cooke RW : Blood Pressure and Cerebral 
Haemorrhage and Ischaemia in Very Low Birthweight Infants.   
 Early Human Development.1989; 19 103-l 10 
19.  Vermont oxford database Website 2010, 
  http://www.vtoxford.org/about/memberlist.aspx 
20. Magasiner VA, Molteno C, Lachman, P et al: Evaluation of the Infant 
at Risk of Neurodevelopmental Disability. S Afr Med J 1999 Oct; 
89(10); 184-7  
21. Laughton, B - The reliability of the Molteno Adapted Scale in 
Predicting Developmental Outcomes at 2 yrs, in Prematurely Born 
Very Low Birth Weight Infants- MSc Neurodevelopment. University of 
Witwatersrand. Thesis submitted 2010 
P a g e  | 31 
 
 
22. Hack M.: Adult Outcomes of Preterm Children. J Dev Behav Pediatr. 
2009 Oct; 30(5):460-70 
23. Cordero L, Timan CJ, Waters HH, et al:	  Mean Arterial Blood 
Pressures During the First 24 Hours of Life in Less than or Equal 
to 600-Gram Birth Weight Infants. Journal of Perinatology 2002; 
22(5):348 – 353 
24. Heygi T, Anwar M, Carbone MT, et al: Blood pressure ranges in 
premature infants. I. The first hours of life. J Pediatrics 1994; 
124:627-33 
25. Bada HS, Korones SB, Perry EH, et al: Mean Arterial Blood Pressure 
Changes in Premature Infants and Those at Risk for Intraventricular 
Haemorrhage. J Pediatr 1990; 117:607-614  
26. Fanaroff JM, Wilson-Costello DE, Newman NS, et al: Treated 
Hypotension is Associated with Neonatal Morbidity and Hearing 
Loss in Extremely Low Birth Weight Infants. Pediatrics 2006 
April117(4):1131-5 
27. Baenziger O, Stolkin F, Keel M, et al: The Influence of the Timing of 
Cord Clamping on Postnatal Oxygenation in Preterm Neonates: A 
Randomized, Controlled Trial.  Pediatrics 2007 Mar; 119(3):455-9 
